HBV cccDNA: Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B

Gut

Volumn 64, Issue 12, 2015, Pages 1972-1984

  Nassal, Michael ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CCCDNA; CIRCULAR DNA; DNA; UNCLASSIFIED DRUG; VIRUS DNA;

ADAPTIVE IMMUNITY; ARTICLE; CHRONIC HEPATITIS B; DISEASE CARRIER; DNA DETERMINATION; DNA METABOLISM; DNA REPAIR; DNA TRANSCRIPTION; EPIGENETICS; EVIDENCE BASED MEDICINE; GENE SILENCING; GENE STRUCTURE; HEPATITIS B VIRUS; HOST CELL; HUMAN; IN VITRO STUDY; INNATE IMMUNITY; LIVER; LONGEVITY; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TREATMENT INDICATION; VIRUS DETECTION; VIRUS ENTRY; VIRUS GENOME; VIRUS REPLICATION; ANIMAL; GENETICS; HEPATITIS B, CHRONIC; METABOLISM; RECURRENT DISEASE; VIROLOGY;

ANIMALS; DNA REPAIR; DNA, CIRCULAR; DNA, VIRAL; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; RECURRENCE; VIRUS REPLICATION;

EID: 84940172646     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309809     Document Type: Article

References (145)

1. Ott JJ, Stevens GA, Groeger J, et al. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30:2212-19.
2. WHO. Hepatitis B. Fact sheet no. 204, updated March 2015. 2008.
3. Chang MH, You SL, Chen CJ, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009;101:1348-55.
4. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. Lancet 2014;384:2053-63.
5. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009;137:1593-608.e1-2.
6. Chevaliez S, Hezode C, Bahrami S, et al. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol 2013;58:676-83.
7. Rehermann B, Ferrari C, Pasquinelli C, et al. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996;2:1104-8.
8. Yan H, Zhong G, Xu G, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife 2012;1:e00049.
9. Ni Y, Lempp FA, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology 2014;146:1070-83.
10. Tong S, Li J. Identification of NTCP as an HBV receptor: the beginning of the end or the end of the beginning? Gastroenterology 2014;146:902-5.
11. Urban S, Bartenschlager R, Kubitz R, et al. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology 2014;147:48-64.
12. Gehring A, Bertoletti A, Tavis JE. Host factor-targeted hepatitis B virus therapies. Intervirology 2014;57:158-62.
13. Guidotti LG, Chisari FV. Immunobiology and pathogenesis of viral hepatitis. Annu Rev Pathol 2006;1:23-61.
14. Protzer U, Maini MK, Knolle PA. Living in the liver: hepatic infections. Nat Rev Immunol 2012;12:201-13.
15. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013;19:859-68.
16. Ferrari C. HBV and the immune response. Liver Int 2015;35(Suppl 1):121-8.
17. Lanford RE, Chavez D, Brasky KM, et al. Isolation of a hepadnavirus from the woolly monkey, a New World primate. Proc Natl Acad Sci USA 1998;95:5757-61.
18. Drexler JF, Geipel A, König A, et al. Bats carry pathogenic hepadnaviruses antigenically related to hepatitis B virus and capable of infecting human hepatocytes. Proc Natl Acad Sci USA 2013;110:16151-6.
19. Dryden KA, Wieland SF, Whitten-Bauer C, et al. Native hepatitis B virions and capsids visualized by electron cryomicroscopy. Mol Cell 2006;22:843-50.
20. Seitz S, Urban S, Antoni C, et al. Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions. EMBO J 2007;26:4160-7.
21. Dane DS, Cameron CH, Briggs M. Virus-like particles in serum of patients with Australia-antigen-associated hepatitis. Lancet 1970;1:695-8.
22. Kenney JM, von Bonsdorff CH, Nassal M, et al. Evolutionary conservation in the hepatitis B virus core structure: comparison of human and duck cores. Structure 1995;3:1009-19.
23. Böttcher B, Wynne SA, Crowther RA. Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy. Nature 1997;386:88-91.
24. Conway JF, Cheng N, Zlotnick A, et al. Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy. Nature 1997;386:91-4.
25. Wynne SA, Crowther RA, Leslie AG. The crystal structure of the human hepatitis B virus capsid. Mol Cell 1999;3:771-80.
26. Gerlich WH, Robinson WS. Hepatitis B virus contains protein attached to the 5′ terminus of its complete DNA strand. Cell 1980;21:801-9.
27. Menne S, Cote PJ. The woodchuck as an animal model for pathogenesis and therapy of chronic hepatitis B virus infection. World J Gastroenterol 2007;13:104-24.
28. Schultz U, Grgacic E, Nassal M. Duck hepatitis B virus: an invaluable model system for HBV infection. Adv Virus Res 2004;63:1-70.
29. Beck J, Nassal M. Hepatitis B virus replication. World J Gastroenterol 2007;13:48-64.
30. Lamas Longarela O, Schmidt TT, Schoneweis K, et al. Proteoglycans act as cellular hepatitis delta virus attachment receptors. PLoS ONE 2013;8:e58340.
31. Sureau C, Salisse J. A conformational heparan sulfate binding site essential to infectivity overlaps with the conserved hepatitis B virus a-determinant. Hepatology 2013;57:985-94.
32. Baumert TF, Meredith L, Ni Y, et al. Entry of hepatitis B and C viruses-recent progress and future impact. Curr Opin Virol 2014;4:58-65.
33. Bruss V. Hepatitis B virus morphogenesis. World J Gastroenterol 2007;13:65-73.
34. Li HC, Huang EY, Su PY, et al. Nuclear export and import of human hepatitis B virus capsid protein and particles. PLoS Pathog 2010;6:e1001162.
35. Schmitz A, Schwarz A, Foss M, et al. Nucleoporin 153 arrests the nuclear import of hepatitis B virus capsids in the nuclear basket. PLoS Pathog 2010;6: e1000741.
36. Bock CT, Schwinn S, Locarnini S, et al. Structural organization of the hepatitis B virus minichromosome. J Mol Biol 2001;307:183-96.
37. Tessarz P, Kouzarides T. Histone core modifications regulating nucleosome structure and dynamics. Nat Rev Mol Cell Biol 2014;15:703-8.
38. Roberts TC, Morris KV, Weinberg MS. Perspectives on the mechanism of transcriptional regulation by long non-coding RNAs. Epigenetics 2014;9:13-20.
39. Venkatesh S, Workman JL. Histone exchange, chromatin structure and the regulation of transcription. Nat Rev Mol Cell Biol 2015;16:178-89.
40. Lucifora J, Arzberger S, Durantel D, et al. Hepatitis B virus X protein is essential to initiate and maintain virus replication after infection. J Hepatol 2011;55:996-1003.
41. Levrero M, Pollicino T, Petersen J, et al. Control of cccDNA function in hepatitis B virus infection. J Hepatol 2009;51:581-92.
42. Ducroux A, Benhenda S, Riviere L, et al. The Tudor domain protein Spindlin1 is involved in intrinsic antiviral defense against incoming hepatitis B Virus and herpes simplex virus type 1. PLoS Pathog 2014;10:e1004343.
43. Tang H, McLachlan A. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. Proc Natl Acad Sci USA 2001;98:1841-6.
44. Cao F, Tavis JE. RNA elements directing translation of the duck hepatitis B Virus polymerase via ribosomal shunting. J Virol 2011;85:6343-52.
45. Nassal M. Hepatitis B viruses: reverse transcription a different way. Virus Res 2008;134:235-49.
46. Cai CW, Lomonosova E, Moran EA, et al. Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity. Antiviral Res 2014;108:48-55.
47. Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 2010;79:181-211.
48. Waters CA, Strande NT, Wyatt DW, et al. Nonhomologous end joining: a good solution for bad ends. DNA Repair (Amst) 2014;17:39-51.
49. Yang W, Summers J. Integration of hepadnavirus DNA in infected liver: evidence for a linear precursor. J Virol 1999;73:9710-17.
50. Sung WK, Zheng H, Li S, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 2012;44:765-9.
51. Ning X, Nguyen D, Mentzer L, et al. Secretion of genome-free hepatitis B virus-single strand blocking model for virion morphogenesis of para-retrovirus. PLoS Pathog 2011;7:e1002255.
52. Prange R. Host factors involved in hepatitis B virus maturation, assembly, and egress. Med Microbiol Immunol 2012;201:449-61.
53. Tuttleman JS, Pugh JC, Summers JW. In vitro experimental infection of primary duck hepatocyte cultures with duck hepatitis B virus. J Virol 1986;58:17-25.
54. Zeisel MB, Lucifora J, Mason WS, et al. Towards an HBV cure: state-of-theart and unresolved questions-report of the ANRS workshop on HBV cure. Gut 2015;64:1314-26.
55. Köck J, Nassal M, MacNelly S, et al. Efficient infection of primary tupaia hepatocytes with purified human and woolly monkey hepatitis B virus. J Virol 2001;75:5084-9.
56. Glebe D, Urban S, Knoop EV, et al. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology 2005;129:234-45.
57. Zhong G, Yan H, Wang H, et al. Sodium taurocholate cotransporting polypeptide mediates woolly monkey hepatitis B virus infection of Tupaia hepatocytes. J Virol 2013;87:7176-84.
58. Dandri M, Lutgehetmann M. Mouse models of hepatitis B and delta virus infection. J Immunol Methods 2014;410:39-49.
59. Foster JR, Lund G, Sapelnikova S, et al. Chimeric rodents with humanized liver: bridging the preclinical/clinical trial gap in ADME/toxicity studies. Xenobiotica 2014;44:109-22.
60. Gripon P, Rumin S, Urban S, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc Natl Acad Sci USA 2002;99:15655-60.
61. Marion MJ, Hantz O, Durantel D. The HepaRG cell line: biological properties and relevance as a tool for cell biology, drug metabolism, and virology studies. Methods Mol Biol 2010;640:261-72.
62. Yang PL, Althage A, Chung J, et al. Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci USA 2002;99:13825-30.
63. Lenhoff RJ, Summers J. Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus. J Virol 1994;68:4565-71.
64. Köck J, Rösler C, Zhang JJ, et al. Generation of covalently closed circular DNA of hepatitis B viruses via intracellular recycling is regulated in a virus specific manner. PLoS Pathog 2010;6:e1001082.
65. Mason WS, Aldrich C, Summers J, et al. Asymmetric replication of duck hepatitis B virus DNA in liver cells: Free minus-strand DNA. Proc Natl Acad Sci USA 1982;79:3997-4001.
66. O'Connell AP, Urban MK, London WT. Naturally occurring infection of Pekin duck embryos by duck hepatitis B virus. Proc Natl Acad Sci USA 1983;80:1703-6.
67. Weiser B, Ganem D, Seeger C, et al. Closed circular viral DNA and asymmetrical heterogeneous forms in livers from animals infected with ground squirrel hepatitis virus. J Virol 1983;48:1-9.
68. Miller RH, Robinson WS. Hepatitis B virus DNA forms in nuclear and cytoplasmic fractions of infected human liver. Virology 1984;137:390-9.
69. Ruiz-Opazo N, Chakraborty PR, Shafritz DA. Evidence for supercoiled hepatitis B virus DNA in chimpanzee liver and serum Dane particles: possible implications in persistent HBV infection. Cell 1982;29:129-36.
70. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982;29:403-15.
71. Zhang YY, Zhang BH, Theele D, et al. Single-cell analysis of covalently closed circular DNA copy numbers in a hepadnavirus-infected liver. Proc Natl Acad Sci USA 2003;100:12372-7.
72. Guo JT, Pryce M, Wang X, et al. Conditional replication of duck hepatitis B virus in hepatoma cells. J Virol 2003;77:1885-93.
73. Liu F, Campagna M, Qi Y, et al. Alpha-interferon suppresses hepadnavirus transcription by altering epigenetic modification of cccDNA minichromosomes. PLoS Pathog 2013;9:e1003613.
74. Königer C, Wingert I, Marsmann M, et al. Involvement of the host DNA-repair enzyme TDP2 in formation of the covalently closed circular DNA persistence reservoir of hepatitis B viruses. Proc Natl Acad Sci USA 2014;111:E4244-53.
75. Lentz TB, Loeb DD. Roles of the envelope proteins in the amplification of covalently closed circular DNA and completion of synthesis of the plus-strand DNA in hepatitis B virus. J Virol 2011;85:11916-27.
76. Volz T, Allweiss L, Ben MM, et al. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol 2013;58:861-7.
77. Köck J, Schlicht HJ. Analysis of the earliest steps of hepadnavirus replication: genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J Virol 1993;67:4867-74.
78. Sun D, Nassal M. Stable HepG2- and Huh7-based human hepatoma cell lines for efficient regulated expression of infectious hepatitis B virus. J Hepatol 2006;45:636-45.
79. Werle-Lapostolle B, Bowden S, Locarnini S, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004;126:1750-8.
80. Margeridon S, Carrouee-Durantel S, Chemin I, et al. Rolling circle amplification, a powerful tool for genetic and functional studies of complete hepatitis B virus genomes from low-level infections and for directly probing covalently closed circular DNA. Antimicrob Agents Chemother 2008;52:3068-73.
81. Wong DK, Yuen MF, Yuan H, et al. Quantitation of covalently closed circular hepatitis B virus DNA in chronic hepatitis B patients. Hepatology 2004;40:727-37.
82. Taranta A, Tien Sy B, Zacher BJ, et al. Hepatitis B virus DNA quantification with the three-in-one (3io) method allows accurate single-step differentiation of total HBV DNA and cccDNA in biopsy-size liver samples. J Clin Virol 2014;60:354-60.
83. Cai D, Nie H, Yan R, et al. A southern blot assay for detection of hepatitis B virus covalently closed circular DNA from cell cultures. Methods Mol Biol 2013;1030:151-61.
84. Wieland SF, Spangenberg HC, Thimme R, et al. Expansion and contraction of the hepatitis B virus transcriptional template in infected chimpanzees. Proc Natl Acad Sci USA 2004;101:2129-34.
85. Seeger C, Sohn JA. Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids 2014;3:e216.
86. Phillips NR, Sprouse ML, Roby RK. Simultaneous quantification of mitochondrial DNA copy number and deletion ratio: a multiplex real-time PCR assay. Sci Rep 2014;4:3887.
87. Zhu Y, Yamamoto T, Cullen J, et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol 2001;75:311-22.
88. Addison WR, Walters KA, Wong WW, et al. Half-life of the duck hepatitis B virus covalently closed circular DNA pool in vivo following inhibition of viral replication. J Virol 2002;76:6356-63.
89. Moraleda G, Saputelli J, Aldrich CE, et al. Lack of effect of antiviral therapy in nondividing hepatocyte cultures on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997;71:9392-9.
90. Murray JM, Wieland SF, Purcell RH, et al. Dynamics of hepatitis B virus clearance in chimpanzees. Proc Natl Acad Sci USA 2005;102:17780-5.
91. Murray JM, Goyal A. In silico single cell dynamics of hepatitis B virus infection and clearance. J Theor Biol 2015;366:91-102.
92. Delmas J, Schorr O, Jamard C, et al. Inhibitory effect of adefovir on viral DNA synthesis and covalently closed circular DNA formation in duck hepatitis B virus-infected hepatocytes in vivo and in vitro. Antimicrob Agents Chemother 2002;46:425-33.
93. Köck J, Baumert TF, Delaney WEt, et al. Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology 2003;38:1410-18.
94. Ashour ME, Atteya R, El-Khamisy SF. Topoisomerase-mediated chromosomal break repair: an emerging player in many games. Nat Rev Cancer 2015;15:137-51.
95. Pommier Y, Huang SY, Gao R, et al. Tyrosyl-DNA-phosphodiesterases (TDP1 and TDP2). DNA Repair (Amst) 2014;19:114-29.
96. Hoeijmakers JH. DNA damage, aging, and cancer. N Engl J Med 2009;361:1475-85.
97. Weitzman MD, Lilley CE, Chaurushiya MS. Genomes in conflict: maintaining genome integrity during virus infection. Annu Rev Microbiol 2010;64:61-81.
98. Turnell AS, Grand RJ. DNA viruses and the cellular DNA-damage response. J Gen Virol 2012;93(Pt 10):2076-97.
99. Luftig MA. Viruses and the DNA damage response: activation and antagonism. Annu Rev Biochem 2014;1:605-25.
100. Weitzman MD, Weitzman JB. What's the damage? The impact of pathogens on pathways that maintain host genome integrity. Cell Host Microbe 2014;15:283-94.
101. Wallace NA, Galloway DA. Manipulation of cellular DNA damage repair machinery facilitates propagation of human papillomaviruses. Semin Cancer Biol 2014;26:30-42.
102. Williams RS, Williams JS, Tainer JA. Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template. Biochem Cell Biol 2007;85:509-20.
103. Paull TT. Mechanisms of ATM Activation. Annu Rev Biochem 2015. 10.1146/annurev-biochem-060614-034335.
104. Tsutakawa SE, Lafrance-Vanasse J, Tainer JA. The cutting edges in DNA repair, licensing, and fidelity: DNA and RNA repair nucleases sculpt DNA to measure twice, cut once. DNA Repair (Amst) 2014;19:95-107.
105. Hartsuiker E, Neale MJ, Carr AM. Distinct requirements for the Rad32(Mre11) nuclease and Ctp1(CtIP) in the removal of covalently bound topoisomerase I and II from DNA. Mol Cell 2009;33:117-23.
106. Quennet V, Beucher A, Barton O, et al. CtIP and MRN promote non-homologous end-joining of etoposide-induced DNA double-strand breaks in G1. Nucleic Acids Res 2011;39:2144-52.
107. Makharashvili N, Tubbs AT, Yang SH, et al. Catalytic and noncatalytic roles of the CtIP endonuclease in double-strand break end resection. Mol Cell 2014;54:1022-33.
108. Cortes Ledesma F, El Khamisy SF, Zuma MC, et al. A human 5′-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage. Nature 2009;461:674-8.
109. Gomez-Herreros F, Romero-Granados R, Zeng Z, et al. TDP2-dependent non-homologous end-joining protects against topoisomerase II-induced DNA breaks and genome instability in cells and in vivo. PLoS Genet 2013;9:e1003226.
110. Nitiss JL, Nitiss KC. Tdp2: a means to fixing the ends. PLoS Genet 2013;9:e1003370.
111. Stahl M, Beck J, Nassal M. Chaperones activate hepadnavirus reverse transcriptase by transiently exposing a C-proximal region in the terminal protein domain that contributes to epsilon RNA binding. J Virol 2007;81:13354-64.
112. Stahl M, Retzlaff M, Nassal M, et al. Chaperone activation of the hepadnaviral reverse transcriptase for template RNA binding is established by the Hsp70 and stimulated by the Hsp90 system. Nucleic Acids Res 2007;35:6124-36.
113. Thompson LH. Recognition, signaling, and repair of DNA double-strand breaks produced by ionizing radiation in mammalian cells: the molecular choreography. Mutat Res 2012;751:158-246.
114. Maede Y, Shimizu H, Fukushima T, et al. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel. Mol Cancer Ther 2014;13:214-20.
115. Song M, Kim YH, Kim JS, et al. Genome engineering in human cells. Methods Enzymol 2014;546:93-118.
116. Cai D, Mills C, Yu W, et al. Identification of disubstituted sulfonamide compounds as specific inhibitors of hepatitis B virus covalently closed circular DNA formation. Antimicrob Agents Chemother 2012;56:4277-88.
117. Reiss S, Rebhan I, Backes P, et al. Recruitment and activation of a lipid kinase by hepatitis C virus NS5A is essential for integrity of the membranous replication compartment. Cell Host Microbe 2011;9:32-45.
118. Protzer U, Nassal M, Chiang PW, et al. Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection. Proc Natl Acad Sci USA 1999;96:10818-23.
119. Wang Z, Wu L, Cheng X, et al. Replication-competent infectious hepatitis B virus vectors carrying substantially sized transgenes by redesigned viral polymerase translation. PLoS ONE 2013;8:e60306.
120. Katen SP, Tan Z, Chirapu SR, et al. Assembly-directed antivirals differentially bind quasiequivalent pockets to modify hepatitis B virus capsid tertiary and quaternary structure. Structure 2013;21:1406-16.
121. Bourne CR, Finn MG, Zlotnick A. Global structural changes in hepatitis B virus capsids induced by the assembly effector HAP1. J Virol 2006;80:11055-61.
122. Zlotnick A, Mukhopadhyay S. Virus assembly, allostery and antivirals. Trends Microbiol 2011;19:14-23.
123. Cai X, Chiu YH, Chen ZJ. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 2014;54:289-96.
124. Hornung V, Hartmann R, Ablasser A, et al. OAS proteins and cGAS: unifying concepts in sensing and responding to cytosolic nucleic acids. Nat Rev Immunol 2014;14:521-8.
125. Murr R. Interplay between different epigenetic modifications and mechanisms. Adv Genet 2010;70:101-41.
126. Belloni L, Pollicino T, De Nicola F, et al. Nuclear HBx binds the HBV minichromosome and modifies the epigenetic regulation of cccDNA function. Proc Natl Acad Sci USA 2009;106:19975-9.
127. Zhang T, Xie N, He W, et al. An integrated proteomics and bioinformatics analyses of hepatitis B virus X interacting proteins and identification of a novel interactor apoA-I. J Proteomics 2013;84:92-105.
128. Slagle BL, Andrisani OM, Bouchard MJ, et al. Technical standards for hepatitis B virus X protein (HBx) research. Hepatology 2015;61:1416-24.
129. Li T, Robert EI, van Breugel PC, et al. A promiscuous alpha-helical motif anchors viral hijackers and substrate receptors to the CUL4-DDB1 ubiquitin ligase machinery. Nat Struct Mol Biol 2010;17:105-11.
130. Marteijn JA, Lans H, Vermeulen W, et al. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat Rev Mol Cell Biol 2014;15:465-81.
131. Reaiche GY, Le Mire MF, Mason WS, et al. The persistence in the liver of residual duck hepatitis B virus covalently closed circular DNA is not dependent upon new viral DNA synthesis. Virology 2010;406:286-92.
132. Chisari FV, Isogawa M, Wieland SF. Pathogenesis of hepatitis B virus infection. Pathol Biol (Paris) 2010;58:258-66.
133. Bertoletti A, Ferrari C. Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection. Gut 2012;61:1754-64.
134. Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity 2014;40:13-24.
135. Mason WS, Xu C, Low HC, et al. The amount of hepatocyte turnover that occurred during resolution of transient hepadnavirus infections was lower when virus replication was inhibited with entecavir. J Virol 2009;83:1778-89.
136. Reaiche-Miller GY, Thorpe M, Low HC, et al. Duck hepatitis B virus covalently closed circular DNA appears to survive hepatocyte mitosis in the growing liver. Virology 2013;446:357-64.
137. Lucifora J, Xia Y, Reisinger F, et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014;343:1221-8.
138. Chisari FV, Mason WS, Seeger C. Virology. Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA." Science 2014;344:1237.
139. Xia Y, Lucifora J, Reisinger F, et al. Virology. Response to Comment on "Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA." Science 2014;344:1237.
140. Lanford RE, Guerra B, Chavez D, et al. GS-9620, an oral agonist of Toll-like receptor-7, induces prolonged suppression of hepatitis B virus in chronically infected chimpanzees. Gastroenterology 2013;144:1508-17, 17.e1-10.
141. Chong CL, Chen ML, Wu YC, et al. Dynamics of HBV cccDNA expression and transcription in different cell growth phase. J Biomed Sci 2011;18:96.
142. Cradick TJ, Keck K, Bradshaw S, et al. Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs. Mol Ther 2010;18:947-54.
143. Weber ND, Stone D, Sedlak RH, et al. AAV-mediated delivery of zinc finger nucleases targeting hepatitis B virus inhibits active replication. PLoS ONE 2014;9:e97579.
144. Bloom K, Ely A, Mussolino C, et al. Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. Mol Ther 2013;21:1889-97.
145. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014;146:1176-92.